Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

Daraxonrasib shrank tumors in over 30% of patients with previously treated RAS-mutant non-small cell lung cancer.

• Why it matters: This finding addresses the limited options for effective treatments in RAS-mutant non-small cell lung cancer, a challenging subset of lung cancers.
• What they did: The study involved testing the first-in-class pan-RAS inhibitor daraxonrasib in patients with advanced lung cancer, observing tumor shrinkage in more than 30% of cases.
• The result: The results support further investigation of daraxonrasib, including ongoing phase III trials, and build on its recent approval for pancreatic cancer.